1 |
M. Lei, W. Lu, W. Meng, M.-C. Parrini, M. J. Eck, B. J. Mayer, and S. C. Harrison, "Structure of PAK1 in an Autoinhibited Conformation Reveals a Multistage Activation Switch", Cell, Vol. 102, pp. 387-397, 2000.
DOI
|
2 |
R. Kumar, A. E. Gururaj, and C. J. Barnes, "p21-activated kinases in cancer", Nat. Rev. Cancer, Vol. 6, pp. 459-471, 2006.
DOI
|
3 |
Z. M. Jaffer and J. Chernoff, "p21-activated kinases: three more join the Pak", Int. J. Biochem. Cell Biol., Vol. 34, pp. 713-717, 2002.
DOI
|
4 |
B. Dummler, K. Ohshiro, R. Kumar, and J. Field, "Pak protein kinases and their role in cancer", Cancer Metast. Rev., Vol. 28, pp. 51-63, 2009.
DOI
|
5 |
C. C. Ong, A. M. Jubb, P. M. Haverty, W. Zhou, V. Tran, T. Truong, H. Turley, T. O'Brien, D. Vucic, A. L. Harris, M. Belvin, L. S. Friedman, E. M. Blackwood, H. Koeppen, and K. P. Hoeflich, "Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells", P. Natl. Acad. Sci. U.S.A., Vol. 108, pp. 7177-7182, 2011.
DOI
|
6 |
A. Balupuri and S. J. Cho, "Exploration of the binding mode of indole derivatives as potent HIV-1 inhibitors using molecular docking simulations", J. Chosun Natural Sci., Vol. 6, pp. 138-142, 2013.
DOI
|
7 |
A. Balupuri, P. K. Balasubramanian, and S. J. Cho, "A CoMFA study of glycogen synthase kinase 3 inhibitors", J. Chosun Natural Sci., Vol. 8, pp. 40-47, 2015.
DOI
|
8 |
A. Balupuri, P. K. Balasubramanian, and S. J. Cho, "A CoMFA study of quinazoline-based anticancer agents", J. Chosun Natural Sci., Vol. 8, pp. 214-220, 2015.
DOI
|
9 |
A. Balupuri, P. K. Balasubramanian, and S. J. Cho, "Comparative molecular field analysis of pyrrolopyrimidines as LRRK2 kinase inhibitors", J. Chosun Natural Sci., Vol. 9, pp. 1-9, 2016.
DOI
|
10 |
P. K. Balasubramanian, A. Balupuri, and S. J. Cho, "A CoMFA study of phenoxypyridine-based JNK3 inhibitors using various partial charge schemes", J. Chosun Natural Sci., Vol. 7, pp. 45-49, 2014.
DOI
|
11 |
W. Lee, J. J. Crawford, I. Aliagas, L. J. Murray, S. Tay, W. Wang, C. E. Heise, K. P. Hoeflich, H. La, S. Mathieu, R. Mintzer, S. Ramaswamy, L. Rouge, and J. Rudolph, "Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors", Bioorg. Med. Chem. Lett., Vol. 26, pp. 3518-3524, 2016.
DOI
|
12 |
SYBYLx2.1, Tripos International, 1699 South Hanley Road, St. Louis, Missouri, 63144, USA.
|
13 |
M. F. Sanner, "Python: a programming language for software integration and development", J. Mol. Graph. Model., Vol. 17, pp. 57-61, 1999.
|
14 |
S. T. Staben, J. A. Feng, K. Lyle, M. Belvin, J. Boggs, J. D. Burch, C. C. Chua, H. Cui, A. G. Dipasquale, L. S. Friedman, C. Heise, H. Koeppen, A. Kotey, R. Mintzer, A. Oh, D. A. Roberts, L. Rouge, J. Rudolph, C. Tam, W. Wang, Y. Xiao, A. Young, Y. Zhang, and K. P. Hoeflich, "Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors", J. Med. Chem., Vol. 57, pp. 1033-1045, 2014.
DOI
|
15 |
G. M. Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew, D. S. Goodsell, and A. J. Olson, "AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility", J. Comput. Chem., Vol. 30, pp. 2785-2791, 2009.
DOI
|
16 |
G. M. Morris, D. S. Goodsell, R. S. Halliday, R. Huey, W. E. Hart, R. K. Belew, and A. J. Olson, "Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function", J. Comput. Chem., Vol. 19, pp. 1639-1662, 1998.
DOI
|